Cephalon Articles
First World Launch Of Insulin-Like Growth Factor
13 February 1995
Monroe Klein Joins Cephalon
12 December 1994
Cephalon Starts Phase III Modafinil Trials
15 August 1994
NEW YORK STOCK COMMENT
4 July 1994
REGENERON PULLS CNTF TRIALS
4 July 1994
TAP SUB-LICENSES CEPHALON TECH
6 June 1994
MYOTROPHIN TESTED FOR POST-POLIO SYNDROME
16 May 1994
CEPHALON APPOINTMENT
11 April 1994
CHIRON LOOKING FLAT AFTER BETASERON HIGH
11 April 1994
REGENERON'S CNTF TRIALS DISAPPOINT
28 March 1994
NEW YORK STOCK COMMENT
17 January 1994
NEUROTROPHIC FACTORS: CHANGING NEUROLOGY
20 December 1993
EURO TRIALS OF MYOTROPHIN
11 October 1993
NEW YORK STOCK COMMENT
6 September 1993
US MODAFINIL TRIAL STARTED
6 September 1993
SMALLER US COMPANIES POST MIXED RESULTS
16 August 1993
MYOTROPHIN DEV'T IN JAPAN
9 August 1993
MERCKLE GAINS LICENSE FROM LAFON
26 July 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
CEPHALON FILES US IND FOR MODAFINIL
19 July 1993
CEPHALON RESEARCH EFFORTS NEAR FRUITION
5 July 1993
ELAN RIGHTS OFFER
14 June 1993
US BIOTECH FIRMS POST GOOD 1st QTRs
17 May 1993
REGENERON STARTS TRIALS
8 February 1993
REGENERON ENTERS PHASE II STUDY
25 January 1993
KYOWA HAKKO'S K252a: US CONTRACT
22 June 1992
WORLD PRODUCT NEWS IN BRIEF
15 June 1992
ALZHEIMER'S DISEASE: US CONCERN
27 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
